Who's at Risk of Alzheimer's? GE and J&J Hope to Find Out
Gilead, Elan and Transition Therapeutics Halt Drug Trials
J&J, Abbott beat expectations: a good sign for pharma results yet to come?
Novartis study shows promise for oral MS therapy
Johnson & Johnson buys a stake in Elan, invests in Alzheimer's program